Chiropractors in Flora, IN Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Dr. Steven A Meeks, D.C, Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 701 E Columbia St, Flora, IN 46929 Phone: 574-967-4900 |
 Flora Chiropractic Center Inc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 701 E Columbia St, Flora, IN 46929 Phone: 574-967-4900 Fax: 574-967-3111 |
Adam Lowell Spesard Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 701 E Columbia St, Flora, IN 46929 Phone: 765-414-3991 Fax: 765-414-3991 |
Flora Chiropractic Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 701 E Columbia St, Flora, IN 46929 Phone: 574-967-4900 Fax: 574-967-3111 |
News Archive
Smoking may increase risk of complications, death after colorectal procedures
​Infection, pneumonia, blood clots and kidney failure are all possible complications after any major surgery. A new study shows that smoking boosts the risk of such complications following some of the most common colorectal procedures, including surgery for colon cancer, diverticulitis or inflammatory bowel disease.
Gene study provides new clues to fight infections
Investigators at The Methodist Hospital Research Institute in Houston examined for the first time the long-term response to strep throat on a genome-wide level, shedding light on how group A streptococcus interacts with the patient's immune system and attempts to circumvent it.
HemaCare second quarter revenue increases to $4.2 million
HemaCare Corporation announced today that the Company generated 2011 second quarter revenue of $4.2 million from continuing operations and a net loss of $252,000, or $(0.03)/share, including net income from discontinued operations of $180,000 compared to second quarter 2010 revenue from continuing operations of $3.9 million and net income of $223,000, or $.02/share, including net income of $843,000 from discontinued operations.
Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Schering-Plough commits to chronic hepatitis C research
Schering-Plough has reaffirmed its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15.
› Verified 2 days ago